Navigation Links
BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production
Date:6/29/2011

BALTIMORE, June 29, 2011 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the availability of BD Recharge™, a chemically defined (CD) cell culture media supplement for biopharmaceutical manufacturing that offers productivity comparable to yeast-based peptones.

"Chemically defined supplements are a significant advance for biopharmaceutical cell culture," said Robert Hallenbeck, Vice President, BD Biosciences – Advanced Bioprocessing.  "BD Recharge provides performance comparable to undefined products, but with greater consistency, which means less risk and lower production costs for biopharmaceutical manufacturers."

The new BD Recharge cell culture media supplement, which was developed using CHO (Chinese hamster ovary) cell lines, eliminates unnecessary constituents to maximize cell viability and protein production.

Peptones are either animal-derived or animal-free supplements that are added to cell culture media to boost protein expression. Although peptones are highly effective, biopharmaceutical manufacturers are increasingly seeking CD alternatives to eliminate the variability and increased regulatory risk inherent in undefined materials.

BD Recharge is the first in a line of next-generation CD, animal-free supplements for the manufacture of biopharmaceuticals. BD Recharge is produced in the Company's fully dedicated animal-free/antibiotic-free (AF2™) facility, which sets a new standard for safety and quality for cell culture media. Products manufactured at the AF2 facility are controlled to the tertiary level — all ingredients, ingredient components and ingredient subcomponents used in the new facility are not of animal origin — significantly reducing the risks that can be associated with mixed-use facilities.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact:
Alyssa Zeff
Public Relations
(201) 847-4358
Alyssa_Zeff@bd.com


'/>"/>
SOURCE BD
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Stanford professor honored for contributions to computational biosciences
2. Challenges for biofuels: New life cycle assessment report from Energy Biosciences Institute
3. Avantra Biosciences teams with TGen Drug Development to assist pharma
4. Human cells can copy not only DNA, but also RNA, says team from Pitt, Helicos BioSciences
5. InQ Biosciences Introduces First Fully Integrated Cell Research System
6. Energy Biosciences Institue named "Deal of Distinction" by tech-transfer group
7. Motorola Solutions Introduces Industrys Most Comprehensive Enterprise Device Management Platform
8. Elsevier introduces Protein Viewer, bringing science to life
9. Orbel Introduces the Board Shielding Wizard
10. Cermetek Introduces Medically Approved Modem Module
11. Olympus introduces the VisiGlide, a single-use guidewire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology: